Office of the Secretary; Notice of Meeting, 58918-58919 [2021-23191]
Download as PDF
jspears on DSK121TN23PROD with NOTICES1
58918
Federal Register / Vol. 86, No. 203 / Monday, October 25, 2021 / Notices
economic threshold and is not
considered a major notice.
The RFA requires agencies to analyze
options for regulatory relief of small
businesses. For purposes of the RFA,
small entities include small businesses,
nonprofit organizations, and small
governmental jurisdictions. Most
hospitals and most other providers and
suppliers are small entities, either by
nonprofit status or by having revenues
of less than $7.5 million to $38.5
million in any 1 year. Individuals and
states are not included in the definition
of a small entity. As we stated in the
RIA for the February 2, 2011 final rule
with comment period (76 FR 5952), we
do not believe that the application fee
will have a significant impact on small
entities.
In addition, section 1102(b) of the Act
requires us to prepare a regulatory
impact analysis if a rule may have a
significant impact on the operations of
a substantial number of small rural
hospitals. This analysis must conform to
the provisions of section 604 of the
RFA. For purposes of section 1102(b) of
the Act, we define a small rural hospital
as a hospital that is located outside of
a Metropolitan Statistical Area for
Medicare payment regulations and has
fewer than 100 beds. We are not
preparing an analysis for section 1102(b)
of the Act because we have determined,
and the Secretary certifies, that this
notice would not have a significant
impact on the operations of a substantial
number of small rural hospitals.
Section 202 of the Unfunded
Mandates Reform Act of 1995 (UMRA)
also requires that agencies assess
anticipated costs and benefits before
issuing any rule whose mandates
require spending in any 1 year of $100
million in 1995 dollars, updated
annually for inflation. In 2021, that
threshold was approximately $158
million. The Agency has determined
that there will be minimal impact from
the costs of this notice, as the threshold
is not met under the UMRA.
Executive Order 13132 establishes
certain requirements that an agency
must meet when it promulgates a
proposed rule (and subsequent final
rule) that imposes substantial direct
requirement costs on state and local
governments, preempts state law, or
otherwise has federalism implications.
Since this notice does not impose
substantial direct costs on state or local
governments, the requirements of
Executive Order 13132 are not
applicable.
B. Costs
The costs associated with this notice
involve the increase in the application
VerDate Sep<11>2014
18:00 Oct 22, 2021
Jkt 256001
fee amount that certain providers and
suppliers must pay in CY 2022. The CY
2022 cost estimates are as follows:
1. Medicare
Based on CMS data, we estimate that
in CY 2022 approximately—
• 10,214 newly enrolling institutional
providers will be subject to and pay an
application fee; and
• 42,117 revalidating institutional
providers will be subject to and pay an
application fee.
Using a figure of 52,331 (10,214 newly
enrolling + 42,117 revalidating)
institutional providers, we estimate an
increase in the cost of the Medicare
application fee requirement in CY 2022
of $1,674,592 (or 52,331 × $32 (or $631
minus $599)) from our CY 2021
projections.
2. Medicaid and CHIP
Based on CMS and state statistics, we
estimate that approximately 30,000
(9,000 newly enrolling + 21,000
revalidating) Medicaid and CHIP
institutional providers will be subject to
an application fee in CY 2022. Using
this figure, we project an increase in the
cost of the Medicaid and CHIP
application fee requirement in CY 2022
of $960,000 (or 30,000 × $32 (or $631
minus $599)) from our CY 2021
projections.
3. Total
Based on the foregoing, we estimate
the total increase in the cost of the
application fee requirement for
Medicare, Medicaid, and CHIP
providers and suppliers in CY 2022 to
be $2,634,592 ($1,674,592 + $960,000)
from our CY 2021 projections.
In accordance with the provisions of
Executive Order 12866, this notice was
reviewed by the Office of Management
and Budget.
The Administrator of the Centers for
Medicare & Medicaid Services (CMS),
Chiquita Brooks-LaSure, having
reviewed and approved this document,
authorizes Lynette Wilson, who is the
Federal Register Liaison, to
electronically sign this document for
purposes of publication in the Federal
Register.
Dated: October 19, 2021.
Lynette Wilson,
Federal Register Liaison, Centers for Medicare
& Medicaid Services.
[FR Doc. 2021–23143 Filed 10–22–21; 8:45 am]
BILLING CODE 4120–01–P
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Library of Medicine; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable materials,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Library of
Medicine Special Emphasis Panel; U24.
Date: December 10, 2021.
Time: 11:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Video Assisted Meeting.
Contact Person: Manana Sukhareva, Ph.D.,
Director, Office of Scientific Review, NIBIB/
NIH, 6707 Democracy Boulevard, Suite 920,
Bethesda, MD 20892–5496, 301–451–3397,
sukharem@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program No. 93.879, Medical Library
Assistance, National Institutes of Health,
HHS)
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–23134 Filed 10–22–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Secretary; Notice of
Meeting
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Interagency Pain
Research Coordinating Committee.
The meeting will be open to the
public. Individuals who plan to
participate and need special assistance,
such as sign language interpretation or
other reasonable accommodations,
should notify the Contact Person listed
below in advance of the meeting.
Name of Committee: Interagency Pain
Research Coordinating Committee.
E:\FR\FM\25OCN1.SGM
25OCN1
58919
Federal Register / Vol. 86, No. 203 / Monday, October 25, 2021 / Notices
Date: November 22, 2021.
Time: 10:00 a.m. to 4:00 p.m. Eastern Time
(ET).
Agenda: The meeting will cover committee
business items including updates on pain
workforce enhancement and pain research
concepts. It will include follow up of IPRCC
recommendations and member updates.
Webcast Live: https://videocast.nih.gov/.
Deadline: Submission of intent to submit
written/electronic statement for comments:
Monday, November 15th, by 5:00 p.m. ET.
Place: National Institutes of Health,
Building 31, 31 Center Drive Bethesda, MD
20892 (Virtual Meeting).
Contact Person: Linda L. Porter, Ph.D.,
Director, Office of Pain Policy and Planning,
Office of the Director, National Institute of
Neurological Disorders and Stroke, NIH, 31
Center Drive, Room 8A31, Bethesda, MD
20892, Phone: (301) 451–4460, Email:
Linda.Porter@nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
The meeting will be open to the public via
NIH Videocast https://videocast.nih.gov/.
Visit the IPRCC website for more
information: https://iprcc.nih.gov. Agenda and
any additional information for the meeting
will be posted when available.
Dated: October 19, 2021.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Heart, Lung, and
Blood Initial Review Group; NHLBI
Institutional Training Mechanism Study
Section.
Date: December 10, 2021.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Health, 6705
Rockledge Drive, Bethesda, MD 20817
(Virtual Meeting).
Contact Person: Lindsay M. Garvin, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health,
6705 Rockledge Drive, Room 208–Y,
Bethesda, MD 20892, (301) 827–7911,
lindsay.garvin@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: October 19, 2021.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–23192 Filed 10–22–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2021–23191 Filed 10–22–21; 8:45 am]
BILLING CODE 4140–01–P
Substance Abuse and Mental Health
Services Administration
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
National Institutes of Health
Periodically, the Substance Abuse and
Mental Health Services Administration
(SAMHSA) will publish a summary of
information collection requests under
OMB review, in compliance with the
Paperwork Reduction Act (44 U.S.C.
chapter 35). To request a copy of these
documents, call the SAMHSA Reports
Clearance Officer at (240) 276–0361.
jspears on DSK121TN23PROD with NOTICES1
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
Project: Minority AIDS InitiativeManagement Reporting Tools (MAI–
MRTs)—(OMB No. 0930–0357)—
Revision
The Substance Abuse and Mental
Health Services Administration
(SAMHSA), Center for Substance Abuse
Prevention (CSAP) is requesting from
the Office of Management and Budget
(OMB) approval for the revised Minority
AIDS Initiative (MAI) monitoring tools,
which includes both youth and adult
questionnaires as well as the quarterly
progress report. This renewal includes
the inclusion of new cohorts.
The cohorts of grantees funded by the
MAI and included in this clearance
request are:
• Capacity Building Initiative 2017
• Capacity Building Initiative 2018
• Prevention Navigators 2017
• Prevention Navigators 2019
• Prevention Navigators 2020
• Prevention Navigators 2021
The target population for the MAI
grantees will be at-risk minority
adolescents and young adults. All MAI
grantees are expected to report their
monitoring data using SAMHSA’s
Strategic Prevention Framework (SPF)
to target minority populations, as well
as other high-risk groups residing in
communities of color with high
prevalence of Substance Abuse and
HIV/AIDS. The primary objectives of the
monitoring tools include:
• Assess the success of the MAI in
reducing risk factors and increasing
protective factorsassociated with the
transmission of the Human
Immunodeficiency Virus (HIV),
Hepatitis C Virus (HCV), and other
sexually transmitted diseases (STD).
• Measure the effectiveness of
evidence-based programs and
infrastructure development activities
such as: Outreach and training,
mobilization of key stakeholders,
substance abuse and HIV/AIDS
counseling and education, testing,
referrals to appropriate medical
treatment and/or other intervention
strategies (i.e., cultural enrichment
activities, educational and vocational
resources, social marketing campaigns,
and computer-based curricula).
• Investigate intervention types and
features that yield the best outcomes for
specific population groups.
• Assess the extent to which access to
health care was enhanced for
population groups and individuals
vulnerable to behavioral health
disparities residing in communities
targeted by funded interventions.
• Assess the process of adopting and
implementing the SPF with the target
populations.
TABLE 1—ESTIMATES OF ANNUALIZED HOUR BURDEN
Number of
respondents
Type of respondent activity
Quarterly Progress Report .................................................
VerDate Sep<11>2014
18:00 Oct 22, 2021
Jkt 256001
PO 00000
Frm 00061
Responses per
respondent
197
Fmt 4703
Sfmt 4703
Total
responses
4
E:\FR\FM\25OCN1.SGM
732
25OCN1
Hours per
response
Total burden
hours
4
2,928
Agencies
[Federal Register Volume 86, Number 203 (Monday, October 25, 2021)]
[Notices]
[Pages 58918-58919]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-23191]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Office of the Secretary; Notice of Meeting
Pursuant to section 10(a) of the Federal Advisory Committee Act, as
amended, notice is hereby given of a meeting of the Interagency Pain
Research Coordinating Committee.
The meeting will be open to the public. Individuals who plan to
participate and need special assistance, such as sign language
interpretation or other reasonable accommodations, should notify the
Contact Person listed below in advance of the meeting.
Name of Committee: Interagency Pain Research Coordinating
Committee.
[[Page 58919]]
Date: November 22, 2021.
Time: 10:00 a.m. to 4:00 p.m. Eastern Time (ET).
Agenda: The meeting will cover committee business items
including updates on pain workforce enhancement and pain research
concepts. It will include follow up of IPRCC recommendations and
member updates.
Webcast Live: https://videocast.nih.gov/.
Deadline: Submission of intent to submit written/electronic
statement for comments: Monday, November 15th, by 5:00 p.m. ET.
Place: National Institutes of Health, Building 31, 31 Center
Drive Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Linda L. Porter, Ph.D., Director, Office of Pain
Policy and Planning, Office of the Director, National Institute of
Neurological Disorders and Stroke, NIH, 31 Center Drive, Room 8A31,
Bethesda, MD 20892, Phone: (301) 451-4460, Email:
[email protected].
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
The meeting will be open to the public via NIH Videocast https://videocast.nih.gov/. Visit the IPRCC website for more information:
https://iprcc.nih.gov. Agenda and any additional information for the
meeting will be posted when available.
Dated: October 19, 2021.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-23191 Filed 10-22-21; 8:45 am]
BILLING CODE 4140-01-P